Mastodon Skip to main content

Posts

Biosion has submitted the IND application for BSI-992, an anti-TROP2 ADC

 Biosion submitted the IND application for BSI-992, a TROP2 ADC, on April 9th, 2024 in China. The TROP2 targeting antibody, discovered by Biosion, was licensed to OBI Pharma in 2021. OBI ADC Technology  OBI Pharma (台灣浩鼎) owns the ex-China right of BSI-992/OBI-992 , with the US FDA clearing  an IND application for a Phase 1/2 Study in Jan 2024. The phase 1 trial in the US is estimated to be completed in 2025Q2. Besides OBI-992, OBI Pharma has also discovered a next-generation anti-TROP2 ADC, OBI-902, using the GlycOBI platform in various drug-antibody ratios (DAR). Furthermore, a BsADC targeting TROP2 and HER2 is currently in the preclinical stage. BSI-992/ OBI-992 OBI-992 is a TROP2-directed antibody-drug-conjugate (ADC) that carries a potent topoisomerase I inhibitor and uses a hydrophilic, enzyme-cleavable linker. Upon binding to TROP2 on the surface of cancer cells, OBI-992 is internalized into the cell and trafficked to lysosomes where the linker is cleaved by cathepsin B, releasin

Innovent initiates the phase 1 study of IBI3001, a B7-H3/EGFR bispecific ADC

 Innovent has initiated a phase 1 study (NCT06349408 ) of IBI3001, a bispecific ADC that targets B7-H3 and EGFR, in patients with solid tumors. Additionally, Innovent is conducting a phase 1 trial ( NCT05774873 ) of IBI344, a bispecific antibody that also targets B7-H3 and EGFR. Schematic overview of crosstalk between the EGFR signaling and the B7/CD28 family Recent research has suggested that the overexpression of novel B7/CD28 family proteins, including B7-H3 may be linked to EGFR signaling and could potentially lead to resistance to EGFR-targeted treatments by promoting an immune-depressed environment within the tumor microenvironment. IBI3001 According to the statement by Innovent, IBI3001 is a  site-specifically glycan-conjugated ADC that consists of a topoisomerase I inhibitor  with  multiple anti-tumor mechanisms of action : (1) enhanced EGFR signaling blockade; (2) EGFR- and B7-H3-aided payload internalization and cytotoxicity; and (3) potent bystander killing effects of ADC

Accutar terminated the clinical trials of AC176 for prostate cancer

 Accutar Biotech has terminated the clinical trials of AC176, an AR PROTAC therapy, for the treatment of prostate cancer. These decisions came after the termination of a clinical trial of AC682, an ER PROTAC treatment in the phase 1 stage. Homepage of Accutar The clinical trials AC176 is an AR-targeting PROTAC drug candidate discovered by Accutar Biotech. The IND application was cleared by both the China NMPA and the US FDA. The clinical trial (NCT05673109/CTR20223355) was started in China, with the first patient receiving the dose in February 2023. Currently, the study has enrolled eight patients as reported on the clinical trial disclosure website. However, the trial was terminated due to changes in the benefit-risk ratio for the subjects at the end of 2023. No further statements were reported regarding this matter. The phase 1 trial (NCT05241613) in the US has enrolled 28 patients and has been terminated for the same reason as above. The trial stopped enrolling new patients in Octob